Skip to main content
. Author manuscript; available in PMC: 2010 May 18.
Published in final edited form as: Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):321–332. doi: 10.1517/17425250902787616

Figure 3.

Figure 3

HCV RNA kinetics described by (A) the CE model, (B, thin line) the PK/PD model and (B, heavy line) the DE model. The CE model can not describe viral rebound. (B) also shows the best-fit of the PK/PD (thin line) and DE models (thick line) to HCV RNA data (filled circles) from a representative patient from 42 during the first week of PEG-IFN α-2b therapy.